We are live on ! Find out more
VKTXW

Viking Therapeutics, Inc.
VKTXW

Delisted

VKTXW was delisted on the 8th of April, 2021.

Back to rankings

3 hedge funds and large institutions have $95K invested in Viking Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 3 → 3 (0)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

44% less capital invested

Capital invested by funds: $169K → $95K (-$74K)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
–
Calls
$46K
Puts
–
Net Calls
+$46K
Net Calls Change
-$46K

Top Buyers

1
PWAM
Park West Asset Management
California
+$17.2K

Top Sellers

1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.24K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$71K -$1.24K -3,100 -1%
PWAM
2
Park West Asset Management
California
$24K +$17.2K +43,100 +82%

VKTXW Hedge Fund Activity: Q2 2017 in Review

3 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics, Inc. (VKTXW) for Q2 2017, worth a combined $95K — down 44% from $169K a quarter earlier.

Fund positioning in VKTXW was balanced in Q2 2017: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Park West Asset Management, adding an estimated $17.2K. The largest seller was Susquehanna International Group, cutting an estimated $1.24K.

  • 3 institutional investors held Viking Therapeutics, Inc. (VKTXW) as of Q2 2017, unchanged from Q1 2017.
  • Funds reported $95K of Viking Therapeutics, Inc. stock for Q2 2017, down 44% quarter-over-quarter.
  • 0 funds opened new Viking Therapeutics, Inc. positions in Q2 2017 and 0 closed out.
  • The largest Viking Therapeutics, Inc. buyer in Q2 2017 was Park West Asset Management, an estimated $17.2K added.
  • The largest Viking Therapeutics, Inc. seller in Q2 2017 was Susquehanna International Group, an estimated $1.24K sold.

Based on aggregated 13F filings for Q2 2017.